Results showed late on Tuesday that the first stage of an American vaccine trial that saw the production of antibodies against "Covid-19" disease caused by infection of the new corona virus, in participants, without the occurrence of serious side effects.
The American pharmaceutical company Moderna is producing the new vaccine, "MRNA-1273", in partnership with the United States government.
The vaccine was injected into the bodies of 45 participants, in the 18-55 age group, beginning in March. Most participants received two doses, and some more.
The US National Institute of Allergy and Infectious Diseases said the system stimulated "elevated levels of neutral antibody activity", higher than the median values in samples from those recovered from "Covid-19".
Last April, the first stage was expanded to include adults over fifty-five, and the results of a possible vaccine trial for them have not yet been announced.
Under the auspices of Moderna, the second phase clinical trials began in early June, and the vaccine is scheduled to be tested on 30,000 participants in the third, final stage, later this month.
Our resource said that the potential vaccine was "generally safe, and good, and no serious adverse effects have been reported to date," adding that it was generally temporary, and was between mild and moderate.